In future clinical practice, the patients with tumors with defective mitophagy can be screened by detecting the expression of mitophagy genes such as Parkin or PINK1 in the patient's tumor tissue, and then the patients are treated with ferroptosis‐inducing therapy, which will greatly promote the therapeutic efficacy of such patients. This evidence concerns the gene PRKN and neoplasm.